POLYMORPHISMS OF EXTRACELLULAR CONNECTIVE TISSUE REMODELING PROTEINASES AND MMP2, MMP3, MMP9 GENES, AND NEOANGIGENESIS VEGF GENE IN RETINAL MICROANGIOPATHY IN THE PATIENTS WITH TYPE 2 DIABETES MELLITUS

The aim of our study was to perform an association analysis between MMP2, MMP3, MMP9, VEGF gene polymorphisms and development of non-proliferative diabetic retinopathy (DR) in the type 2 diabetic patients (DM).

201 DM patients: 90 cases of DR and 111 subjects without DR features were included into the study. Polymorphic variants of MMP2 (rs2438650), MMP3 (rs3025058), MMP9 (rs3918242), and VEGF (rs699947 and rs3025039) genes were assayed. The genetic typing was carried out by restriction fragment length polymorphism and TaqMan methods.

The analysis of complex genotypes at the five polymorphic positions has revealed some significant findings in positive and negatively incorporated complexes. Increased frequencies of MMP2-1306 CC genotype in the group of patients with “early” development of complication, and more frequent combination of high-level HbA1c with MMP2-1306CC and MMP9-1562CT genotypes were shown in DR patients. Computerassisted modelling with visual reconstruction of network interactions between the genotypes involved into the destruction events and angiogenesis, as well as altered HbA1с levels (an integral parameter of glycemia), has revealed some differences in structural and functional organization of gene-gene and gene- protein interactions between the groups of patients with DR versus those without this disorder. Сonclusion. A design of interactome biological networks based on transcription regulation and metabolic pathways, as well as their topological analysis allows to build and study interactions of genes and proteins, with reference to pathogenetic studies of DM2 complications aiming for development of approaches to personalized prevention and therapy in future times.

1. Klimontov V.V., Tyan N.V., Orlov N.B., Shevchenko A.V., Prokofiev V.F., Myakina N.E., Bulumbaeva D.M., Konenkov V.I. Association of serum levels and gene polymorphism of vascular endothelium growth factor with coronary artery disease in type 2 diabetic patients. Kardiologiya = Сardiology, 2017, Vol. 57, no. 5, pp. 17-22.(In Russ.)

2. Abu El-Asrar A., Midena E., Al-Shabrawey M., Mohammad G. New developments in the pathophysiology and management of diabetic retinopathy. J. Diabetes Res., 2013, Vol. 2013, 424258. doi: 10.1155/2013/424258.

3. Banyasz I., Szabo S., Bokodi G., Vannay A., Vásárhelyi B., Szabó A., Tulassay T., Rigó J. Genetic polymorphisms of vascular endothelial growth factor in severe preeclampsia. Mol. Hum. Reprod., 2006, Vol. 12, pp. 233-236.

4. Belo V., Luizon M., Carneiro P., Gomes V., Lacchini R., Lanna C., Souza-Costa D. Effect of metabolic syndrome risk factors and MMP-2 genetic variations on circulating MMP-2 levels in childhood obesity. Mol. Biol. Rep., 2013, Vol. 40, no. 3, pp. 2697-704.

5. Beránek M., Kolar P., Tschoplova S., Kankova K., Vasku A. Genetic variations and plasma levels of gelatinase A (matrix metalloproteinase-2) and gelatinase B (matrix metalloproteinase-9) in proliferative diabetic retinopathy. Mol. Vis., 2008, Vol. 14, pp. 1114-1121.

6. Busti C., Falcinelli E., Momi S., Gresele P. Matrix metalloproteinases and peripheral arterial disease. Intern. Emerg. Med., 2009, Vol. 5, pp. 13-25.

7. Csermely P., Korcsmáros T., Kiss H.J., London G., Nussinov R. Structure and dynamics of molecular networks: a novel paradigm of drug discovery: a comprehensive review. Pharmacol. Ther., 2013, Vol. 138, no. 3, pp. 333-408.

8. Di Y., Nie Q.-Z., Chen X.-L. Matrix metalloproteinase-9 and vascular endothelial growth factor expression change in experimental retinal neovascularization. Int. J. Ophthalmol., 2016, Vol. 9, no. 6, pp. 804-808.

9. Fattah A., Eltanamly R., Nabih M., Kamal M. Vascular endothelial growth factor gene polymorphism is not associated with diabetic retinopathy in egyptian patients. Middle East Afr. J. Ophthalmol., 2016, Vol. 23, no. 1, pp. 75-78.

10. Gong J., Sun Y. Association of VEGFgene polymorphisms with diabetic retinopathy: a meta-analysis. PLoS ONE, 2013, Vol. 8, no. 12, e84069. doi: 10.1371/journal.pone.0084069.

11. Guo L., Jiang F., Tang Y.-T., Si M.-Y., Jiao X.-Y. The association of serum vascular endothelial growth factor and ferritin in diabetic microvascular disease. Diabetes Technol. Ther., 2014, Vol. 16, no. 4, pp. 224-234.

12. Guo L., Lyu H. Meta analysis of the association between vascular endothelial growth factor -2578 C/A polymorphism and risk for diabetic retinopathy. Chin. J. Exp. Ophthalmol., 2015, Vol. 33, no. 1, pp. 70-75.

13. Han L., Zhang L., Xing W., Zhuo R., Lin X.L., Hao Y., Wu Q., Zhao J. The associations between VEGF gene polymorphisms and diabetic retinopathy susceptibility: a meta-analysis of 11 case-control studies review article. J. Diabetes Res., 2014, Vol. 2014, 805801. doi:10.1155/2014/805801.

14. Kowluru R., Zhong Q., Santos J. Matrix metalloproteinases in diabetic retinopathy: potential role of MMP-9. Expert Opin. Investig. Drugs, 2012, Vol. 21, no. 6, pp. 797-805.

15. Kuo J., Wong T., Rotter J. Challenges in elucidating the genetics of diabetic retinopathy. JAMA Ophthalmol., 2014, Vol. 132, no. 1, pp. 96-107.

16. Lvovs D., Favorova O.O., Favorov A.V. A polygenic approach to the study of polygenic diseases. Acta Naturae, 2012, Vol. 4, no. 3, pp. 62-76.

17. Metzger S., Koutsimpelas D., Brieger J. Transcriptional regulation of the VEGF gene in dependence of individual genomic variations. Cytokine, 2015, Vol. 76, no. 2, pp. 519-526.

18. Mohammad G., Kowluru R. Matrix metalloproteinase-2 in the development of diabetic retinopathy and mitochondrial dysfunction. Lab. Invest., 2010, Vol. 90, pp. 1365-1372.

19. Okamoto K., Mimura K., Murawak Y., Yuasa I. Association of functional gene polymorphisms of matrix metalloproteinase MMP-1, MMP-3 and MMP-9 with the progression of chronic liver disease. J. Gastr. Hepatol., 2005, Vol. 20, no. 7, pp. 1102-1108.

20. Opdenakker G. Matrix metalloproteinase in diabetic retinopathy. Acta Ophthalmologica, 2015, Vol. 93, S. 255.

21. Peeters S., Engelen L., Buijs J., Chaturvedi N., Fuller J., Schalkwijk C., Stehouwer C. Plasma levels of matrix metalloproteinase-2, -3, -10, and tissue inhibitor of metalloproteinase-1 are associated with vascular complications in patients with type 1 diabetes: the EURODIAB Prospective Complications Study. Cardiovasc. Diabetol., 2015, Vol. 14, p. 31

22. Price S., Greaves D.,Watkins H. Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele specific transcriptional regulation. J. Biol. Chem., 2001, Vol. 276, pp. 7549-7558.

23. Shannon P., Markiel A., Ozier O., Baliga N.S., Wang J.T.,Ramage D., Amin N., Schwikowski B., Ideker T. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res., 2003, Vol. 13, no. 11, pp. 2498-2504.

24. Singh M., Tyagi S. Metalloproteinases as mediators of inflammation and the eyes: molecular genetic underpinnings governing ocular pathophysiology. Int. J. Ophthalmol., 2017, Vol. 10, no. 8, pp. 1308-1318.

25. Sun J., Keenan H., Cavallerano J., Asztalos B., Schaefer E., Sell D., Strauch C., Monnier V., Doria A., Aiello L., King G. Protection from retinopathy and other complications in patients with type 1 diabetes of extreme duration: the Joslin 50-Year Medalist Study. Diabetes Care, 2011, Vol. 34, no. 4, pp. 968-974.

26. Takahashi M., Haro H., Wakabayashi Y., Kawa-Uchi T., Komori H., Shinomiya K. The association of degeneration of the intervertebral disc with 5a/6a polymorphism in the promoter of the human matrix metalloproteinase-3 gene. J. Bone Joint Surg., 2001, Vol. 83 (B), pp. 491-495.

27. Tarallo S., Beltramo E., Berrone E., Dentelli P., Porta M. Effects of high glucose and thiamine on the balance between matrix metalloproteinases and their tissue inhibitors in vascular cells. Acta Diabetologica, 2010, Vol. 7, no. 2, pp. 105-111.

28. Tsai W.-C., Liang F.-C., Cheng J.-W., Lin L.-P., Chang S.-C., Chen H.-H., Pang J.-H.S. High glucose concentration up-regulates the expression of matrix metalloproteinase-9 and -13 in tendon cells. BMC Musculoskeletal Disorders, 2013, Vol. 14, p. 255.

29. Xie X.-J., Yang Y.-M., Jiang J.-K., Lu Y.-Q. Association between the vascular endothelial growth factor single nucleotide polymorphisms and diabetic retinopathy risk: a meta-analysis. J. Diabetes, 2017, Vol. 9, no. 8, pp. 738-753.

30. Yang J., Fan X.-H., Guan Y.Q., Li Y., Sun W., Yang X.-Z., Liu R.MMP-2gene polymorphisms in type 2 diabetes mellitus diabetic retinopathy. Int. J. Ophthalmol., 2010, Vol. 3, no. 2, pp. 137-140.

31. Yang J., Zhang T., Cui X., Ma Y., Wang H. Correlation of polymorphism of MMP-3 gene with the risk of type 2 diabetic retinopathy.Ann. Eye Sci., 2016, Vol. 31, no. 3. doi: 10.3978/j.issn.1000-4432.2016.09.11.

32. Yuen M., Chow W., Lam K. Diabetic retinopathy: from pathophysiology to treatment. Review Article. HKJ Ophthalmol., 2016, Vol. 20, no. 3, pp. 106-108.

33. Zhong Q., Kowluru R.A. Regulation of matrix metalloproteinase-9 by epigenetic modifications and the development of diabetic retinopathy. Diabetes, 2013, Vol. 62, no. 7, pp. 2559-2568.